3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
27
Neoplasms
3
Neoplasm Metastasis
3
Metastatic Castration-Resistant Prostate Cancer
3
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Follicular
1
Colorectal Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bites and Stings
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Bevacizumab
3
durvalumab
2
atezolizumab
2
Nivolumab
2
Ipilimumab
2
Hepatectomy
2
tremelimumab
1
trastuzumab deruxtecan
1
poly ICLC
1
pembrolizumab
1
brodalumab
1
Whole Genome Sequencing
1
Standard of Care
1
Specimen Handling
1
Radionuclide Imaging
1
Pluvicto
1
Platinum
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Immunoglobulin G
1
IMC-001
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Disulfides
1
Diathermy
1
Cisplatin
1
Cell- and Tissue-Based Therapy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
enzalutamide
×
30 days
×
Clear all
No trials found.